The Administrative Core provides the infrastructure for and coordinates all activities of the MPN Research Consortium (MPN-RC). Key functions include organizational management and communication, resource allocation and financial management (personnel, funds, equipment, and supplies), organization of all internal and external advisory boards and committees, scientific and clinical trials oversight to ensure regulatory compliance and procedural implementation, and external liaison to appropriate governmental agencies.
The specific aims of the Administrative Core are: 1) Coordinate the activities of all MPN-RC Projects and Cores and monitor progress in the Projects and effective use of shared resource Cores; 2) Schedule and provide optimal staff support for all MPN-RC committees and boards; 3) Assure that research involving the use of human subjects and vertebrate animals is pursued in compliance with NIH regulations; 4) Establish all contracts with participating organizations and administer and oversee all budgets and the disperal of funds; 5) Liaison to the NCI for all matters pertaining to the MPN-RC; 6) Develop and negotiate budgets and contracts with pharmaceutical companies to gain access to drugs for clinical trials to be pursued by Project 4; 7) Develop criteria for institutional membership in the MPN-RC and assist in membership applications and site initiation visits. In addition, monitor performance of all members to assure that they are optimally functioning in a fashion that merits their continued participation, 8) Prepare yearly progress reports to be submitted to the NCI. Orchestrate the resubmission of this competitive renewal application to the NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA108671-10A1
Application #
9416776
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587
Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179
Ling, Te; Crispino, John D; Zingariello, Maria et al. (2018) GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol 11:169-184

Showing the most recent 10 out of 195 publications